| Patent application number | Description | Published |
|---|
| 20100325527 | OVERLAY FOR DIGITAL ANNOTATIONS - A user input is received as a digital annotation, and the digital annotation is maintained as at least part of an overlay layer. The digital annotation is displayed, and if information from a program is being displayed then the digital annotation is displayed concurrently with the information from the program. Interaction between the overlay layer and the application layer can also be allowed. | 12-23-2010 |
| 20110064012 | WIRELESS SUPPORT FOR PORTABLE MEDIA PLAYER DEVICES - A portable media player device is capable of operating in a wireless network. The wireless portable media player device can bootstrap and synchronize with an ad hoc network with low power consumption. Neighbor portable media player devices in an ad hoc network can be discovered by the wireless portable media player device. The portable media player device can establish and terminate connections to neighbor portable media player devices. The portable media player device can transfer data in a high speed data transfer mode or a power save data transfer mode, while concurrently permitting discovery by other devices. The portable media player device operates in a power save mode during an inactive portion of a periodic discovery interval. | 03-17-2011 |
| 20110072036 | PAGE-BASED CONTENT STORAGE SYSTEM - A page-based content storage system may be provided by a method of managing content which includes generating, from a plurality of electronic files containing displayable content, a plurality of viewpages, where each viewpage contains one or more portions of the displayable content and each viewpage is displayable in a single-page view. The method further includes assembling the viewpages into a journal to provide a page-based storage structure configured to enable individual, selective management of the viewpages based on properties associated with the one or more portions of the displayable content. The method further includes visually presenting the viewpages as single-page views accessible via a page-based user interface of a computing system. | 03-24-2011 |
| 20110310118 | Ink Lag Compensation Techniques - Ink lag compensation techniques are described. In implementations, an input is recognized by a computing device as an ink stroke to be rendered on a display device of the computing device. An extension is predicted, by the computing device, to be applied to the ink stroke that is likely to be subsequently input in conjunction with the ink stroke. The ink stroke and the extension are output for concurrent display on the display device of the computing device. | 12-22-2011 |
| 20120233343 | MEDIA DEVICE PRESENCE MANAGEMENT - A media player may be adapted to manage presence information distribution and access to facilitate media communication between compatible devices. Devices connecting in an ad-hoc or other network topology include a plurality of presence settings that determine how or if the device appears to be available for communication to other devices over the network. Additionally, the presence settings identify other, specific devices or groups of devices that may communicate with a device. By comparing the presence settings of a sending device with the settings of a receiving device, the receiving device may determine a presence state for all devices within communication range. | 09-13-2012 |
| Patent application number | Description | Published |
|---|
| 20160097586 | METHOD FOR ETHANE LIQUEFACTION WITH DEMETHANIZATION - The process for liquefying a gaseous stream received from a pipeline that is comprised predominantly of ethane and a relatively small amount of other components by using a mixed refrigerant loop incorporating heavy hydrocarbons, as well as a distillation column to remove constituents lighter than ethane. | 04-07-2016 |
| 20160097587 | APPARATUS FOR ETHANE LIQUEFACTION WITH DEMETHANIZATION - The apparatus for liquefying a gaseous stream received from a pipeline that is comprised predominantly of ethane and a relatively small amount of other components by using a mixed refrigerant refrigeration cycle loop incorporating heavy hydrocarbons, as well as a distillation column to remove constituents lighter than ethane. | 04-07-2016 |
| 20160097588 | METHOD FOR ETHANE LIQUEFACTION WITH DEMETHANIZATION - The process for liquefying a gaseous stream received from a pipeline that is comprised predominantly of ethane and a relatively small amount of other components by using a mixed refrigerant loop incorporating heavy hydrocarbons (butane, and/or pentane), as well as a distillation column to remove constituents lighter than ethane. Prior to cooling in a main heat exchanger, the gaseous stream is split into two fractions. The first fraction is cooled in the main heat exchanger and introduced to the distillation column. The second fraction is expanded to produce a two phase fluid, with the liquid fraction being introduced to the distillation column below the first fraction, and the gas fraction being cooled and then introduced to the distillation column at a point above the first fraction. | 04-07-2016 |
| 20160097589 | APPARATUS FOR ETHANE LIQUEFACTION WITH DEMETHANIZATION - The apparatus for liquefying a gaseous stream received from a pipeline that is comprised predominantly of ethane and a relatively small amount of other components by using a mixed refrigerant refrigeration cycle loop incorporating heavy hydrocarbons, as well as a distillation column to remove constituents lighter than ethane. Prior to cooling in a main heat exchanger, the gaseous stream is split into two fractions. The main heat exchanger is configured to cool the first fraction before heading to the distillation column for separation therein. An expansion device expands the second fraction to produce a two phase fluid, which is separated in a gas/liquid separator, with the liquid fraction being introduced to the distillation column below the first fraction, and the gas fraction being cooled and then introduced to the distillation column at a point above the first fraction. | 04-07-2016 |
| Patent application number | Description | Published |
|---|
| 20090130228 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND OR CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS - This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics. | 05-21-2009 |
| 20100129387 | PHARMACEUTICAL COMPOSITION CONTAINING THE NMB0606 PROTEIN - The present invention is related to field of medicine, particularly to the development of pharmaceutical formulation containing NMB0606 protein. Formulation described in this invention is able to confer protection against different diseases caused or not by pathogenic agents. NMB0606 protein was identified as a | 05-27-2010 |
| 20150030700 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND/OR CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS - This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemothearapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa and velcade (bortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics. | 01-29-2015 |
| 20150111832 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT AND/OR CHEMOSENSIBILIZATION OF REFRACTORY TUMORS TO ANTICANCER DRUGS - This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomycin C, imatinib, iressa, velcade (bortezomib), cytarabine (Ara C), fludarabine and mitroxantrone. The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics. | 04-23-2015 |
| Patent application number | Description | Published |
|---|
| 20110113008 | Workflow automation system and method - The workflow automation system is a secure online web-based system that automates any office workflow in a minimal amount of time by providing appropriate customizations and ASP.net forms, the customizations including name of the system, task-names, role names, names of actions on each task, order of tasks, etc. After the customizations, the workflow automation system is executable to provide each role; a secure login with a central HR repository; an application that the role is responsible for; active task(s) in the application, etc. The desired web forms can be made in ASP.net using the provided templates for forms, and controls to define what to do when by whom. The workflow automation system includes automatic sending of e-mail reminders to complete tasks after certain administrator-defined intervals, application tracking, parallel and sequential task processing, easy concealment of certain role names from others, and an easy method to provide Instructions on each web page. | 05-12-2011 |
| 20130124254 | WORKFLOW AUTOMATION SYSTEM AND METHOD - The workflow automation system is a secure, online web-based system that automates any office workflow in a minimal amount of time by providing appropriate customizations and ASP.net forms, the customizations including name of the system, task-names, role names, names of actions on each task, order of tasks, etc. After the customizations, the workflow automation system is executable to provide each role a secure login with a central HR repository; an application that the role is responsible for; active task(s) in the application, etc. The desired web forms can be made in ASP.net using provided templates for forms, and controls to define what to do when by whom. The workflow automation system includes automatic sending of e-mail reminders to complete tasks after certain administrator-defined intervals, application tracking, parallel and sequential task processing, easy concealment of certain role names from others, and an easy method to provide Instructions on each web page. | 05-16-2013 |
| Patent application number | Description | Published |
|---|
| 20130261473 | DEVICES, SYSTEMS AND METHODS FOR EFFICIENT IDENTIFICATION OF IMPROVED CRT PARAMETERS - Methods, systems and devices efficiently identify cardiac resynchronization therapy (CRT) pacing parameter set(s) that provide improved hemodynamic response relative to an initial CRT pacing parameter set, wherein each CRT pacing parameter set includes at least two CRT pacing parameters. User input(s) are accepted that specify a maximum amount of time and/or parameter sets that can be used to perform testing, and specify relative importance of parameters within the sets. Based on the accepted user input(s), there is a determination of how many different variations of each of the CRT pacing parameters can be tested, and based on this determination different CRT pacing parameter sets are selected and tested to obtain a hemodynamic response measure corresponding to each of the different sets tested. Additionally, one or more of the tested CRT pacing parameter sets, if any, that provide improved hemodynamic response relative to the initial CRT pacing parameter set is/are identified. | 10-03-2013 |
| 20160067501 | DEVICES, SYSTEMS AND METHODS FOR EFFICIENT IDENTIFICATION OF IMPROVED CRT PARAMETERS - Methods, systems and devices efficiently identify cardiac resynchronization therapy (CRT) pacing parameter set(s) that provide improved hemodynamic response relative to an initial CRT pacing parameter set, wherein each CRT pacing parameter set includes at least two CRT pacing parameters. User input(s) are accepted that specify a maximum amount of time and/or parameter sets that can be used to perform testing, and specify relative importance of parameters within the sets. Based on the accepted user input(s), there is a determination of how many different variations of each of the CRT pacing parameters can be tested, and based on this determination different CRT pacing parameter sets are selected and tested to obtain a hemodynamic response measure corresponding to each of the different sets tested. Additionally, one or more of the tested CRT pacing parameter sets, if any, that provide improved hemodynamic response relative to the initial CRT pacing parameter set is/are identified. | 03-10-2016 |
